Scott Shurmur, MD
Interventional Cardiology · Lubbock, TXNPI 1447201355
Payments from drug & device makers
Across 106 payments — averaging $187.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$10K
- Sanofi-aventis U.S. LLC$4K
- Amgen$2K
- Abbott$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Medicure Pharma Inc.$500
- plus $1K from 13 others
What the payments were for
- Consulting fees$3,80043%
- Travel & lodging$1,08612%
- Food & beverage$3,72442%
- Education$2032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 24 | $9,913 |
| Sanofi-aventis U.S. LLC | 9 | $3,586 |
| Amgen | 3 | $1,769 |
| Abbott | 16 | $1,592 |
| Regeneron Healthcare Solutions, Inc. | 24 | $1,219 |
| Medicure Pharma Inc. | 1 | $500 |
| Medtronic | 9 | $433 |
| Edwards Lifesciences | 5 | $135 |
| Heartflow, Inc. | 1 | $120 |
| Akcea Therapeutics, Inc. | 2 | $119 |
| Abiomed | 2 | $102 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $100 |
| Regeneron | 1 | $99 |
| Kowa Pharmaceuticals America, Inc. | 1 | $59 |
| Philips North America LLC | 2 | $34 |
| Cardiovascular Systems Inc. | 1 | $34 |
| Stryker | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRALUENT$3,890
- Mitra Clip system$1,010
- ZYPITAMAG (pitavastatin)$500
- COREVALVE EVOLUT R$253
- Repatha$126
- TEGSEDI$100
How this compares
$19,859 in reported general payments places this provider in the 65th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 40 | $50,256 |
| Praluent PenAlirocumab | 36 | $17,928 |
| XareltoRivaroxaban | 16 | $11,765 |
| Repatha SureclickEvolocumab | 13 | $6,719 |
| Nebivolol Hcl | 108 | $5,248 |
| Rosuvastatin Calcium | 193 | $2,778 |
| Ezetimibe | 52 | $1,122 |
| Lisinopril | 102 | $773 |
| Amlodipine Besylate | 94 | $729 |
| Carvedilol | 74 | $726 |
| Ramipril | 53 | $688 |
| Amiodarone Hcl | 16 | $640 |
| Losartan Potassium | 52 | $559 |
| Atorvastatin Calcium | 80 | $500 |
| Pravastatin Sodium | 34 | $484 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Lubbock
- Mohammad AnsariLubbock$961K
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
- Jeffrey CarrTyler$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.